Rapamycin Plus Bevacizumab in Advanced Cancers
The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.
Advanced Cancer|Metastatic Cancer
DRUG: Rapamycin (liquid)|DRUG: Bevacizumab|DRUG: Rapamycin (Tablets)
Toxicity, 3 weeks
Response, 6 weeks|Pharmacokinetics, 3 weeks
The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.